Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal Failure, AV-Node Blockers, Shock and Hyperkalemia Syndrome by Diribe, Nnaemeka & Le, Jacqueline
UC Irvine
Clinical Practice and Cases in Emergency Medicine
Title
Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal Failure, AV-Node Blockers, 
Shock and Hyperkalemia Syndrome
Permalink
https://escholarship.org/uc/item/4sw4n693
Journal
Clinical Practice and Cases in Emergency Medicine, 3(3)
ISSN
2474-252X
Authors
Diribe, Nnaemeka
Le, Jacqueline
Publication Date
2019
DOI
10.5811/cpcem.2019.5.43118
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Clinical Practice and Cases in Emergency Medicine 282 Volume III, no. 3: August 2019
Case RepoRt
 
Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal 
Failure, AV-Node Blockers, Shock and Hyperkalemia Syndrome
 
Nnaemeka Diribe, DO
Jacqueline Le, MD 
Section Editors: Joel Moll, MD and Rick A. McPheeters, DO           
Submission history: Submitted March 17, 2019; Revision received May 6, 2019; Accepted May 20, 2019 
Electronically published July 22, 2019         
Full text available through open access at http://escholarship.org/uc/uciem_cpcem   
DOI: 10.5811/cpcem.2019.5.43118
BRASH (bradycardia, renal failure, atrioventricular-node blockers, shock, and hyperkalemia) 
syndrome is a recently coined term for a condition that describes the severe bradycardia and 
shock associated with hyperkalemia in patients on atrioventricular (AV)-node blocking agents. 
The proposed pathophysiology involves a precipitating event that exacerbates renal dysfunction 
with resulting AV-node blocker and potassium accumulation that act synergistically to precipitate 
bradycardia and hypotension. This syndrome may be refractory to the usual management of 
bradycardia. This case describes BRASH syndrome precipitated by trimethoprim/sulfamethoxazole. 
[Clin Pract Cases Emerg Med. 2019;3(3):282-285.]
INTRODUCTION
Severe hyperkalemia can present as reversible 
bradycardia that mimics atrioventricular (AV) block.1 
However, hyperkalemia in the setting of concomitant AV-
node blocker usage can precipitate refractory bradycardia and 
hemodynamic instability even without a critically elevated 
potassium level or sizeable ingestion of AV-node blocking 
agents. This syndrome termed BRASH – bradycardia, renal 
failure, AV-node blockers, shock and hyperkalemia –is a 
cycle of synergy between hyperkalemia and AV-blockade that 
can result in cardiovascular collapse.2 It would generally be 
expected that the prevalence of such a condition be higher 
among the elderly who may be more likely to be on AV-node 
blocking medications and have a greater likelihood of events 
that precipitate renal failure.3 We report a case of BRASH 
syndrome occurring in a relatively young patient following a 
course of trimethoprim/sulfamethoxazole (TMP/SMX).
CASE REPORT
A 51-year-old male with past medical history of pituitary 
carcinoma with resection, metastasis to the liver, Cushing’s 
syndrome, hypertension, hyperlipidemia, hypothyroidism, 
insulin dependent diabetes mellitus, and renal insufficiency 
presented to the emergency department (ED) after a syncopal 
episode at the office of his primary care physician (PCP). He 
was found to have a pulse of 20 beats per minute (bpm) and 
Desert Regional Medical Center, Department of Emergency Medicine, Palm 
Springs, California
blood pressure of 60/30 millimeters of mercury (mmHg) by 
paramedics who immediately initiated transcutaneous pacing 
and transported him to the ED. On arrival, the patient was 
somnolent but arousable, paced at 90 bpm at 70 milliamps, 
and persistently hypotensive with blood pressure of 80/60 
mm Hg. Pacer capture was poor. His electrocardiogram 
(ECG) revealed third-degree AV block and marked 
bradycardia with heart rate of 39 bpm, peaked T waves, and 
widened QRS of 173 milliseconds (Image). The patient’s 
bradycardia was refractory to atropine, and pacing was 
resumed. Initial laboratory data was significant for elevated 
serum potassium of 8.6 millimoles per liter (mmol/L) 
(reference range 3.5 – 4.9 mmol/L), blood urea nitrogen 
(BUN) of 51 milligrams per deciliter (mg/dL) (reference 
range 8 – 26 mg/dL), and creatinine of 3.3 mg/dL (reference 
range 0.6 – 1.3 mg/dL). 
According to his PCP, his baseline creatinine level was 
1.7 mg/dL. Sodium was low at 130 mmol/L (reference range 
138 – 146 mmol/L), and troponin I was normal at 0.010 ng/
mL (reference range 0.000 – 0.080ng/mL). Intravenous (IV) 
calcium chloride, insulin with dextrose, and albuterol were 
administered to treat his hyperkalemia. IV hydrocortisone 
was additionally given for potential adrenal crisis. With 
treatment, his heart rate and blood pressure improved 
to 97 bpm and 140/52 mmHg, respectively. His level of 
consciousness likewise was restored. Nephrology was 
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CPC-EM Capsule
What do we already know about this clinical entity? 
Atrioventricular-node blockers and 
hyperkalemia may act in synergy to precipitate 
bradycardia and shock that may be refractory to 
usual individual therapy.
What makes this presentation of disease reportable? 
This case highlights bradycardia, renal failure, 
AV-node blockers, shock and hyperkalemia 
(BRASH) syndrome and the potentially grave 
risk associated with prescribing medications 
that can cause hyperkalemia.
What is the major learning point? 
Bradycardia and shock from BRASH syndrome 
require intervention at multiple physiologic fronts 
that individually may not be grossly abnormal.
How might this improve emergency medicine 
practice? 
Algorithmic and heuristic recognition of this 
syndrome could aid rapid intervention by the 
emergency physician and improve potential 
morbidity and mortality.
contacted for possible dialysis, and the patient was admitted 
to the intensive care unit. 
It was later discovered that the patient’s medications 
included the beta-blocker carvedilol (6.25 mg twice daily) 
and eplerenone (25 mg daily), a potassium-sparing diuretic. 
He denied any recent dosage changes or attempted overdose. 
Interestingly, he had been started on TMP/SMX for otitis 
media a week prior to presentation and had developed 
progressive weakness and fatigue three days after his first 
dose. He was being evaluated on an outpatient basis for said 
weakness when he had the syncopal episode. His hospital 
course consisted of continued therapy with additional 
diuresis and sodium polystyrene sulfonate, resulting in the 
down trending of serum potassium levels and improvement 
of his renal function and urine output. Within 24 hours, 
his potassium level corrected to 5.0 mmol/L, and therefore 
dialysis was not initiated. Upon discharge three days 
later, his potassium was 4.1 mmol/L, BUN 31 mg/dL, and 
creatinine 1.4 mg/dL. He was instructed to stop taking his 
eplerenone and was discharged in stable condition with 
scheduled outpatient follow-up.
DISCUSSION
Hyperkalemia is a well-known reversible cause of heart 
block, arrhythmia, and syncope.3 It can be precipitated 
and worsened by multiple factors including medications, 
renal failure, mineralocorticoid deficiency, tissue necrosis, 
metabolic derangement and exogenous intake.4 Risk 
factors for medication-induced hyperkalemia include 
Image. Initial electrocardiogram of 51-year-old male showing third-degree atrioventricular block with a ventricular escape rhythm. There is 
marked bradycardia (39 beats/minute), peaked T waves, and widened QRS (173 milliseconds).
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diabetes mellitus, renal insufficiency, hypoaldosteronism, 
and age greater than 60 years.5 There have been multiple 
documented cases of hyperkalemia precipitated by TMP/
SMX as sole therapy6,7 or in combination with other 
medications.8 In fact, hyperkalemia and acute renal 
dysfunction have been documented with onset after therapy 
initiation in as quickly as 24 hours, particularly in patients 
with baseline renal insufficiency.9 This is due to the direct 
activity of the trimethoprim component of TMP/SMX in 
inhibiting potassium excretion by reversibly disrupting 
sodium reabsorption by cells in the distal nephron.10 
There may also be elements of renal toxicity driven 
by sulfamethoxazole crystal deposition.11 Moreover, 
eplerenone is an aldosterone antagonist that inhibits renal 
secretion of potassium and sodium reabsorption, whereas 
carvedilol is a beta blocker that suppresses catecholamine-
driven renin release while impairing cellular potassium 
uptake.4 Our patient was therefore on several prescribed 
medications with the potential to drive and worsen 
hyperkalemia. Particularly interesting is the notion that beta 
blockers can act in synergy with hyperkalemia to induce 
bradycardia even with only mild hyperkalemia present.3 
This is achieved by the dual role beta blockers play as 
direct AV-node blockers in addition to maintaining higher 
serum potassium levels by reducing potassium excretion 
and impairing cellular uptake of serum potassium.4 This 
cycle is propagated as bradycardia worsens renal perfusion 
leading to a spiral of worsening hyperkalemia, renal failure 
and bradycardic shock, which can sometimes be refractory 
to usual therapy.2 
ACLS
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Figure. Management considerations for BRASH – bradycardia, 
renal failure, atrioventricular-node blockers, shock, and 
hyperkalemia – syndrome.
Given the pathophysiology described above, it is 
reasonable to expect that the population most susceptible to 
this syndrome would include the elderly who are often on 
multiple medications with potential to block the AV node 
or depress renal function, as well as patients with baseline 
renal insufficiency or heart block.3,4 It is important to note 
that patients presenting with BRASH syndrome may be 
adherent to the prescribed doses of the AV-node blocker 
and have not ingested additional significant quantities of 
the medication. There may be, however, a precipitating 
event such as the addition of a new medication with the 
potential to cause hypovolemia or exacerbate baseline renal 
insufficiency. In this case, the initiation of antibiotic therapy 
with TMP/SMX worsened our patient’s already-known renal 
insufficiency and on top of the eplerenone and carvedilol he 
was taking, contributed to his overall marked hyperkalemia 
and bradycardia. Furthermore, a stress corticosteroid was not 
used during the treatment of his ear infection.
Management of BRASH syndrome involves supportive 
care, treatment of shock, and expeditious correction of 
electrolyte abnormalities (Figure). As is standard with 
severe symptomatic hyperkalemia, membrane stabilization 
must be initiated with IV administration of calcium, insulin 
and dextrose, beta-agonist therapy and diuresis or dialysis 
as needed. Volume status must be evaluated carefully and 
addressed since acutely anuric patients can experience 
fluid overload while others may be fluid depleted. Patients 
may require support with vasopressors if shock remains 
despite other therapies, in which case epinephrine and 
isoproterenol could be reasonable choices given their beta-
receptor activity.2
CONCLUSION
BRASH – bradycardia, renal failure, AV-node blockers, 
shock and hyperkalemia – is a syndrome of severe bradycardic 
shock that is likely propagated by a synergy between AV-node 
blockade and hyperkalemia. The patients are generally on 
only prescribed doses of the AV-node blocker and present with 
severe bradycardia and hypotension after a precipitating event 
that worsens renal function. In some cases, such as the one 
presented here, the shock is severe enough to cause syncope. 
Mindfulness of the populations most likely to develop 
BRASH syndrome is recommended to help avoid prescribing 
medications that can potentially worsen renal function and 
predispose an already vulnerable patient to this syndrome. 
Immediate recognition of BRASH syndrome is likewise 
imperative to ensure prompt and aggressive management.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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